Navigation Links
Regeneron Announces Presentation at the ISI Annual Conference
Date:2/8/2011

TARRYTOWN, N.Y., Feb. 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the ISI Annual Conference on Tuesday, February 15, 2011.  The presentation is scheduled for 2:10 p.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through March 17, 2011.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7800michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:7/31/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named ... by Crain,s Detroit Business . ... by three-year revenue growth. This year,s edition measures growth from ... view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... triumph," said Phil Hagerman , CEO and chairman of ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, awarding him $1000 ... is in his third year at the University of California, Los Angeles majoring in ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... company based in Vero Beach, announced today that two of their associates were ... that represents professionally managed senior living communities in Florida. The awards were announced ...
(Date:8/16/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to Test Country, ... the United States has undergone major changes over the last decade, particularly when it ... order to get a blood test or other lab work done. Today, most tests ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence ... pelvic pain. In addition to oncology services, the new center will specialize ... (abnormal heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar ...
Breaking Medicine News(10 mins):